CSIMarket Company Name, Ticker, Industry, else..
 
Cingulate Inc   (CING)
Other Ticker:  
 
 
Price: $5.1700 $0.22 4.444%
Day's High: $5.35 Week Perf: -20.58 %
Day's Low: $ 4.92 30 Day Perf: -70.77 %
Volume (M): 266 52 Wk High: $ 20.83
Volume (M$): $ 1,376 52 Wk Avg: $3.98
Open: $4.92 52 Wk Low: $0.21



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Cingulate Inc
Cingulate Inc is a neurotechnology company that focuses on developing innovative solutions aimed at improving brain health and performance. The company uses advanced technologies to create non-invasive, personalized, and scalable tools that can be utilized in various industries, including healthcare, sports, and education. Cingulate Inc specializes in the development of brain computer interface (BCI) systems, wearable devices, and software applications that can assess brain activity, provide neurofeedback, and enhance cognitive functions. Their products and services are designed to help individuals optimize their brain states, enhance mental well-being, and achieve peak performance.


   Company Address: 1901 W. 47th Kansas City 66205 KS
   Company Phone Number: 942-2300   Stock Exchange / Ticker: NASDAQ CING


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Cingulate's Strategic Move Signals Robust Growth Potential

Published Fri, Jun 28 2024 1:15 PM UTC


In a significant development, Cingulate Inc., a Kansas City-based biopharmaceutical company, has recently announced the immediate exercise of a substantial number of Series A and Series B warrants, leading to gross proceeds of $1.86 million. This move showcases the company's commitment to advancing its pipeline of next-generation pharmaceutical products, leveraging its ...
Stock Market Announcement

Cingulate Inc. Successfully Closes Public Offering, Demonstrating Strong Investor Confidence Amidst Promising Pipeline of Pharmaceutical Products

Published Tue, Feb 6 2024 9:15 PM UTC



KANSAS CITY, Kan., Feb. 06, 2024 - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) recently announced the successful completion of its public offering, marking a significant milestone in the advancement of its pipeline of next-generation pharmaceutical products. With its proprietary Precision Timed Release (PTR) drug delivery platform technology, Cingulate ...
Financing Agreement

Werth Family Investment Associates Converts Remaining $33M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Published Mon, Jan 29 2024 11:45 AM UTC

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
Kansas City, Kan. - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) has recently made an exciting announcement regarding its latest financial developments. Werth Family Investment Associates, LLC (WFIA), the manager of which is Peter...
Product Service News

Cingulate's Precision Timed Release Therapy for Anxiety Receives FDA Guidance, Shaping a New Era in Treatment

Published Fri, Dec 1 2023 2:00 PM UTC


Introduction
Cingulate Inc., a biopharmaceutical company focused on developing next-generation pharmaceutical products, has announced receiving guidance from the Food and Drug Administration (FDA) on moving forward with its investigational asset CTx-2103 (buspirone) to combat anxiety. This development is a significant step in addressing the growing prevalence of anx...
Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com